Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients

Bullous pemphigoid (BP) is the most common autoimmune blistering disease in Europe and its treatment can be challenging. Several published cases have reported dupilumab efficiency in treatment-refractory patients. We conducted a retrospective multicentric study of 36 patients to evaluate the real-li...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) 2023-07, Vol.189 (2), p.244-246
Main Authors: Moghadam, Parna, Tancrede, Emmanuelle, Bouaziz, Jean-David, Kallout, Julien, Bedane, Christophe, Begon, Edouard, Bourgault-Villada, Isabelle, Calugareanu, Andreea, Dereure, Olivier, Jendoubi, Fatma, Pham-Ledard, Anne, Ingen-Housz-Oro, Saskia, Picard-Dahan, Catherine, Viguier, Manuelle, Mahevas, Thibault, Jachiet, Marie, Charvet, Estelle, Cassius, Charles, Alexandre, Marina, Lepelletier, Clémence
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bullous pemphigoid (BP) is the most common autoimmune blistering disease in Europe and its treatment can be challenging. Several published cases have reported dupilumab efficiency in treatment-refractory patients. We conducted a retrospective multicentric study of 36 patients to evaluate the real-life efficiency of dupilumab in BP. Our results suggest that dupilumab, in association with high-potency topical steroids, could be rapidly effective in various clinical forms of BP and seems to be well tolerated in the elderly.
ISSN:0007-0963
1365-2133
DOI:10.1093/bjd/ljad136